Edgewise 制药

最新新闻

• RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $59
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  Oppenheimer Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $51
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• 评级变动
  Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $52
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• Analysts Are Bullish on These Healthcare Stocks: Prime Medicine, Inc. (PRME), Edgewise Therapeutics (EWTX)
  TipRanks · 2026/9/25
• 评级变动
  J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• H.C. Wainwright Initiates Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 评级变动
  H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $55
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/6/6
• 评级变动
  J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/20
• 评级变动
  J.P. Morgan Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $45
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Lexeo Therapeutics, Inc. (LXEO) and Edgewise Therapeutics (EWTX)
  TipRanks · 2026/9/23
• 评级变动
  A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $41 to $59
  \u5e02\u573a\u8d44\u8baf · 2026/6/18
• 评级变动
  H.C. Wainwright Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/6/3
• 评级变动
  Guggenheim Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $51
  \u5e02\u573a\u8d44\u8baf · 2026/7/6
• 评级变动
  Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $52
  \u5e02\u573a\u8d44\u8baf · 2026/6/2

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。